"The launch of LEQSELVI in the U.S. brings an effective, new treatment option for severe alopecia areata to eligible patients and the healthcare providers who treat them," said Richard Ascroft, CEO, ...

Sun Pharmaceutical Industries Limited announced Leqselvi (deuruxolitinib) 8 mg tablets is now available to healthcare providers and people living with severe alopecia areata in the US. Leqselvi is ...

LEQSELVI has been approved by the US FDA, following strong results from clinical trials and is now available to adults ...

Sun Pharma shares rose nearly 2 per cent on Tuesday after the company launched Leqselvi, a new treatment for severe alopecia ...

LEQSELVI has shown rapid results in clinical trials, with one-third of patients regaining nearly full scalp hair by Week 24.

Mumbai: Sun Pharmaceutical Industries Limited has announced the launch of LEQSELVI (deuruxolitinib) 8 mg tablets in the U.S.

Leqselvi (deuruxolitinib) 8 mg tablets are approved for adults with severe alopecia areata, a disease that causes the immune system to attack hair follicles, leading to partial or complete hair loss ...

Sun Pharma settles litigation with Incyte over Leqselvi, launches product for severe alopecia areata treatment in the US.

In a regulatory filing on Monday, Sun Pharma announced that it has reached a settlement and licensing agreement with Incyte ...

The delay in Sun Pharma's launch of Leqselvi in the US was caused by a patent infringement case, which was later settled in a ...

Sun recieved approval from the US Food and Drug Administration for Leqselvi in July 2024. Soon after the regulator’s approval ...

Sun Pharmaceutical Industries Ltd has launched LEQSELVI (deuruxolitinib) 8 mg tablets, a new treatment for severe alopecia ...